Analyst Viewpoint
Rise in antibiotic resistance of bacteria is projected to spur innovation and growth in the global hospital infection therapeutics market. Advancements in diagnostics and drug delivery methods are also anticipated to boost market statistics. Rise in geriatric population is another factor driving the demand for hospital infection therapeutics, since this group is more prone to hospital-acquired infections due to weakened immune system.
Emerging economies present high growth potential to drug manufacturers, with individuals in such countries seeking improved healthcare services owing to the rise in general income levels. Investments in R&D in non-antibiotic treatment options and partnerships for co-development and commercialization of anti-infective agents are likely to further bolster the hospital infection therapeutics market size.
Hospital-acquired infections are a common occurrence in the healthcare sector. In low and medium income countries, the presence of unsanitary environments in and around hospitals is a major contributory factor to hospital-acquired infections.
Faulty sterilization procedures and lack of medical facility infection control solutions in these settings also result in an increase in the occurrence of hospital-acquired diseases. Rise in infections caused by resistant bacteria is augmenting the global hospital therapeutics market development.
Companies operating in the global landscape are investing in research and development activities to produce new antibiotics. However, growth in treatment resistance, requirement of large investments due to high attrition rates in clinical trials, and dearth of reimbursement policies are resulting in a restricted pipeline of medications. This is likely to hamper the hospital infection therapeutics market value to a certain extent.
Over time, microorganisms such as fungi and bacteria develop resistance to drugs that are designed to eliminate them. Thus, they continue to thrive, causing infections among the population. Such resistant infections can often be difficult to treat.
Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly five million deaths in 2019. More than 2.8 million antimicrobial-resistant infections are reported each year in the U.S.
People at any stage of life can be affected by antibiotic resistance. It has the potential to derail industries such as healthcare and agriculture industries. Thus, antibiotic resistance is one of the key public health issues across the world.
Growth in initiatives such as the WHO's Global Action Plan on Antimicrobial Resistance and related programs is likely to augment the demand for anti-bacterial medications during the forecast period. This, in turn, is expected to result in an increase in awareness about hospital infectious disease treatments.
Technological developments in diagnostics, drug delivery, and therapy monitoring are bolstering the sales of healthcare facility infection control drugs. Development of rapid diagnostic tests and point-of-care devices is assisting healthcare personnel in swiftly diagnosing and treating hospital-acquired infections. This is resulting in better patient outcomes and lower risk of infection transmission.
Telemedicine and digital health platforms also increase patient access to healthcare services and allow for remote monitoring of patients with hospital-acquired infections. Furthermore, development of innovative drug delivery technologies, such as nanoparticles and liposomes, enhances treatment efficacy and minimizes toxicity, thereby increasing the effectiveness of hospital infection therapy.
As per the global hospital infection therapeutics industry analysis, Europe accounted for significant share of the global industry in 2022. High incidence of hospital-acquired infections, rise in number of surgeries and the resultant hospitalizations, increase in the elderly population, and growth in spending on advanced healthcare are driving the region’s hospital infection therapeutics market share.
North America is another region that is recording significant hospital infection therapeutics market expansion. Presence of highly developed health care infrastructure and larger reimbursement coverage are propelling the market dynamics of the region.
Future analysis of hospital infection therapeutics reveals that the high growth rate of the pharmaceutical industry in India and China is expected to sustain the market trajectory in Asia Pacific. Companies are increasingly investing in China for the development of novel treatment approaches for hospital-acquired infections. These key trends in Asia Pacific are expected to hold strong through 2031.
The hospital infection therapeutics market report scope includes an analysis of key players operating in the global market. Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company are the prominent companies in the global landscape.
Leading companies such as Merck & Co., Inc. and Pfizer, Inc. are engaged in the manufacture of anti-bacterial drugs. These companies are also investing substantially in research and development activities to overcome drug resistance.
The research report on hospital infection therapeutics market summarizes the prominent players in terms of parameters such as company overview, portfolio, recent developments, business segments, growth strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 11.3 Bn |
| Market Forecast Value in 2031 | US$ 14.4 Bn |
| Growth Rate (CAGR) | 2.6% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 11.3 Bn in 2022
It is likely to grow at a CAGR of 2.6% from 2023 to 2031
Rise in antibiotic resistance of bacteria spurring innovation in hospital infection therapeutics, and advancements in diagnostics and drug delivery methods
The anti-bacterial drugs segment commands a bulk of the share
Europe was the leading region in 2022
Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company.
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hospital Infection Therapeutics Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry
6. Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Therapeutics, 2017-2031
6.3.1. Anti-bacterial Drugs
6.3.2. Anti-fungal Drugs
6.3.3. Anti-viral Drugs
6.3.4. Others
6.4. Market Attractiveness, by Therapeutics
7. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Infection
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Infection, 2017-2031
7.3.1. Hospital Acquired Pneumonia
7.3.2. Urinary Tract Infections
7.3.3. Gastrointestinal Disorders
7.3.4. Bloodstream Infections
7.3.5. Surgical Site Infections
7.3.6. Other Hospital Infections
7.4. Market Attractiveness, by Infection
8. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Hospital Infection Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Therapeutics, 2023-2031
9.2.1. Anti-bacterial Drugs
9.2.2. Anti-fungal Drugs
9.2.3. Anti-viral Drugs
9.2.4. Others
9.3. Market Value Forecast, by Infection, 2023-2031
9.3.1. Hospital Acquired Pneumonia
9.3.2. Urinary Tract Infections
9.3.3. Gastrointestinal Disorders
9.3.4. Bloodstream Infections
9.3.5. Surgical Site Infections
9.3.6. Other Hospital Infections
9.4. Market Value Forecast, by Country, 2023-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapeutics
9.5.2. By Infection
9.5.3. By Country
10. Europe Hospital Infection Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapeutics, 2023-2031
10.2.1. Anti-bacterial Drugs
10.2.2. Anti-fungal Drugs
10.2.3. Anti-viral Drugs
10.2.4. Others
10.3. Market Value Forecast, by Infection, 2023-2031
10.3.1. Hospital Acquired Pneumonia
10.3.2. Urinary Tract Infections
10.3.3. Gastrointestinal Disorders
10.3.4. Bloodstream Infections
10.3.5. Surgical Site Infections
10.3.6. Other Hospital Infections
10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapeutics
10.5.2. By Infection
10.5.3. By Country/Sub-region
11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapeutics, 2023-2031
11.2.1. Anti-bacterial Drugs
11.2.2. Anti-fungal Drugs
11.2.3. Anti-viral Drugs
11.2.4. Others
11.3. Market Value Forecast, by Infection, 2023-2031
11.3.1. Hospital Acquired Pneumonia
11.3.2. Urinary Tract Infections
11.3.3. Gastrointestinal Disorders
11.3.4. Bloodstream Infections
11.3.5. Surgical Site Infections
11.3.6. Other Hospital Infections
11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Therapeutics
11.5.2. By Infection
11.5.3. By Country/Sub-region
12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Therapeutics, 2023-2031
12.2.1. Anti-bacterial Drugs
12.2.2. Anti-fungal Drugs
12.2.3. Anti-viral Drugs
12.2.4. Others
12.3. Market Value Forecast, by Infection, 2023-2031
12.3.1. Hospital Acquired Pneumonia
12.3.2. Urinary Tract Infections
12.3.3. Gastrointestinal Disorders
12.3.4. Bloodstream Infections
12.3.5. Surgical Site Infections
12.3.6. Other Hospital Infections
12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Therapeutics
12.5.2. By Infection
12.5.3. By Country/Sub-region
13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Therapeutics, 2023-2031
13.2.1. Anti-bacterial Drugs
13.2.2. Anti-fungal Drugs
13.2.3. Anti-viral Drugs
13.2.4. Others
13.3. Market Value Forecast, by Infection, 2023-2031
13.3.1. Hospital Acquired Pneumonia
13.3.2. Urinary Tract Infections
13.3.3. Gastrointestinal Disorders
13.3.4. Bloodstream Infections
13.3.5. Surgical Site Infections
13.3.6. Other Hospital Infections
13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Therapeutics
13.5.2. By Infection
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Merck & Co., Inc.
14.3.1.1. Company Revenue
14.3.1.2. Business Overview
14.3.1.3. Product Segments
14.3.1.4. Geographic Footprint
14.3.1.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.1.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.2. Pfizer, Inc.
14.3.2.1. Company Revenue
14.3.2.2. Business Overview
14.3.2.3. Product Segments
14.3.2.4. Geographic Footprint
14.3.2.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.2.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Revenue
14.3.3.2. Business Overview
14.3.3.3. Product Segments
14.3.3.4. Geographic Footprint
14.3.3.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.3.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.4. AstraZeneca
14.3.4.1. Company Revenue
14.3.4.2. Business Overview
14.3.4.3. Product Segments
14.3.4.4. Geographic Footprint
14.3.4.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.4.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.5. Johnson & Johnson Services, Inc.
14.3.5.1. Company Revenue
14.3.5.2. Business Overview
14.3.5.3. Product Segments
14.3.5.4. Geographic Footprint
14.3.5.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.5.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Revenue
14.3.6.2. Business Overview
14.3.6.3. Product Segments
14.3.6.4. Geographic Footprint
14.3.6.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.6.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.7. Bayer AG
14.3.7.1. Company Revenue
14.3.7.2. Business Overview
14.3.7.3. Product Segments
14.3.7.4. Geographic Footprint
14.3.7.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.7.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.8. Allergan plc.
14.3.8.1. Company Revenue
14.3.8.2. Business Overview
14.3.8.3. Product Segments
14.3.8.4. Geographic Footprint
14.3.8.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.8.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.9. Sanofi S.A.
14.3.9.1. Company Revenue
14.3.9.2. Business Overview
14.3.9.3. Product Segments
14.3.9.4. Geographic Footprint
14.3.9.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.9.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.10. Gilead Sciences, Inc.
14.3.10.1. Company Revenue
14.3.10.2. Business Overview
14.3.10.3. Product Segments
14.3.10.4. Geographic Footprint
14.3.10.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.10.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.11. Basilea Pharmaceutica Ltd.
14.3.11.1. Company Revenue
14.3.11.2. Business Overview
14.3.11.3. Product Segments
14.3.11.4. Geographic Footprint
14.3.11.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.11.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
14.3.12. Bristol-Myers Squibb Company
14.3.12.1. Company Revenue
14.3.12.2. Business Overview
14.3.12.3. Product Segments
14.3.12.4. Geographic Footprint
14.3.12.5. Production Capacity/Plant Details, etc. (*As Applicable)
14.3.12.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.
List of Tables
Table 1: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 2: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2017-2031
Table 3: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 4: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 5: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 6: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2017-2031
Table 7: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 8: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 9: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection 2017-2031
Table 10: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 11: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 12: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2017-2031
Table 13: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 15: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection 2017-2031
Table 16: Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017-2031
Table 18: Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection 2017-2031
List of Figures
Figure 1: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 2: Global Hospital Infection Therapeutics Market Value Share, by Therapeutics, 2022
Figure 3: Global Hospital Infection Therapeutics Market Value Share, by Infection, 2022
Figure 4: Global Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 5: Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 6: Global Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031
Figure 7: Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023-2031
Figure 8: Global Hospital Infection Therapeutics Market Value Share Analysis, by Region, 2022 and 2031
Figure 9: Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
Figure 10: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 11: North America Hospital Infection Therapeutics Market Value Share Analysis, by Country, 2022 and 2031
Figure 12: North America Hospital Infection Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
Figure 13: North America Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 14: North America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 15: North America Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031
Figure 16: North America Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023-2031
Figure 17: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 18: Europe Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 19: Europe Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 20: Europe Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 21: Europe America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 22: Europe Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031
Figure 23: Europe Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023-2031
Figure 24: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 25: Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Asia Pacific Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 27: Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 28: Asia Pacific America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 29: Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031
Figure 30: Asia Pacific Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023-2031
Figure 31: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017-2031
Figure 32: Latin America Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Latin America Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 34: Latin America Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031
Figure 35: Latin America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 36: Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 37: Middle East & Africa Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Middle East & Africa America Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2023-2031
Figure 39: Middle East & Africa America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023-2031
Figure 40: Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031
Figure 41: Middle East & Africa Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023-2031
Figure 42: Global Hospital Infection Therapeutics Market Share Analysis, by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Hospital Infection Therapeutics Market
